Showing 1 posts of 1 posts found.
AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after reaching its pre-specified stopping criteria. …
Weber is new CMO at Sensorion
Charity commits £800,000 to AI research into late breast cancer recurrence
AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over
Acumentis CEO Herspiegel steps down as Burden assumes role
Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia